Published in final edited form as:

Addiction. 2016 January ; 111(1): 117–128. doi:10.1111/add.13161.

Comparative Effectiveness of Motivation Phase Intervention Components for Use with Smokers Unwilling to Quit: A Factorial Screening Experiment

Jessica W. Cook^{1,2,3}, Linda M. Collins⁶, Michael C. Fiore^{1,2}, Stevens S. Smith^{1,2}, David Fraser^{1,2}, Daniel M. Bolt⁴, Timothy B. Baker^{1,2}, Megan E. Piper^{1,2}, Tanya R. Schlam^{1,2}, Douglas Jorenby^{1,2}, Wei-Yin Loh⁵, and Robin Mermelstein⁷

¹University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, 1930 Monroe St., Suite 200, Madison, WI 53711

²University of Wisconsin School of Medicine and Public Health, Department of Medicine, 1685 Highland Avenue, 5158 Medical Foundation Centennial Building, Madison, WI 53705

³William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705

⁴University of Wisconsin, Department of Educational Psychology, 1025 W. Johnson St., Madison, WI 53706

⁵University of Wisconsin, Department of Statistics, 1220 Medical Sciences Center, 1300 University Ave., Madison, WI 53706

⁶The Pennsylvania State University, The Methodology Center and Department of Human Development & Family Studies, 404 Health and Human Development Building, University Park, PA 16802

⁷University of Illinois at Chicago, Institute for Health Research and Policy, 544 Westside Research Office Bldg., 1747 West Roosevelt Rd., Chicago, IL 60608

Abstract

Aims—To screen promising intervention components designed to reduce smoking and promote abstinence in smokers initially unwilling to quit.

Design—A balanced, 4-factor, randomized factorial experiment.

Setting—Eleven primary care clinics in southern Wisconsin, USA.

Participants—517 adult smokers (63% women, 91% White) recruited during primary care visits who were willing to reduce their smoking but not quit.

Interventions—Four factors contrasted intervention components designed to reduce smoking and promote abstinence: 1) nicotine patch vs. none; 2) nicotine gum vs. none; 3) motivational

Declaration of Interest:

The authors have received no direct or indirect funding from, nor do they have a connection with, the tobacco, alcohol, pharmaceutical or gaming industries or anybody substantially funded by one of these organizations.

Clinical Trial Registration: NCT01122238

interviewing (MI) vs. none; and 4) behavioral reduction counseling (BR) vs. none. Participants could request cessation treatment at any point during the study.

Measurements—The primary outcome was percent change in cigarettes smoked per day at 26 weeks post-study enrollment; the secondary outcomes were percent change at 12 weeks and point-prevalence abstinence at 12 and 26 weeks post-study enrollment.

Findings—There were few main effects, but a significant 4-way interaction at 26-weeks post-study enrollment ($p=.01$, $\beta = .12$) revealed relatively large smoking reductions by two component combinations: nicotine gum combined with BR and BR combined with MI. Further, BR improved 12-week abstinence rates ($p=.04$), and nicotine gum, when used without MI, increased abstinence after a subsequent aided quit attempt ($p=.01$).

Conclusions—Motivation-phase nicotine gum and behavioral reduction counseling are promising intervention components for smokers who are initially unwilling to quit.

Keywords

Smoking reduction; smoking cessation; multiphase optimization strategy (MOST); Phase-Based Model; nicotine replacement therapy; comparative effectiveness; primary care; chronic care smoking treatment; factorial experiment; Motivational Interviewing

Over 40 million Americans continue to smoke [1] despite the enormous harms of tobacco use [2]. More smokers would quit if a greater proportion were offered and accepted evidence-based treatment during their healthcare visits [3]. However, only about 5–20% of smokers initiate cessation treatment during a healthcare visit (e.g., [2, 4–6]), in part because the vast majority (70–90%) are not willing to commit to quitting smoking at a given clinic visit [5–7]. Because so few smokers are not ready to quit at any given time, typical smoking treatments offered by healthcare systems (*i.e.*, *cessation treatments*) are unused by the majority of smokers who are unwilling to quit smoking. Even when smokers do receive cessation treatment, only a minority succeed in quitting long-term [3]. Thus, two critical public health goals are to: 1) successfully recruit smokers who are unwilling to quit into evidence-based smoking reduction treatment at healthcare visits and 2) increase the success of their quit attempts. This research addresses both goals.

This research was guided by the Multiphase Optimization Strategy (MOST; [8–11]) and the Phase-Based Model (PBM) of smoking treatment [12–14]. MOST is a research strategy that uses efficient designs (e.g., factorial experiments [11]) to screen multiple intervention components to identify those warranting further investigation. The PBM holds that there are different phases of smoking cessation (*i.e.*, Motivation, Preparation, Cessation, Maintenance, and Relapse Recovery), each presenting its own challenges and opportunities, and emphasizes the need to identify components that work especially well at each phase. This is one of four linked articles. One [12] reviews the theory and methods behind this research. The others report factorial experiments of intervention components for the Motivation (this experiment) [15], the Preparation/Cessation [16], and Maintenance [17] phases of smoking treatment.

The current experiment screens intervention components for smokers in the Motivation phase of smoking intervention – those initially unwilling to quit. These components are designed to engage smokers in treatment, help them reduce their smoking, and enhance their success if they ultimately attempt to quit. MOST and PBM are complementary; MOST affords the evaluative screening of multiple intervention components, and the PBM suggests the types of components that should be screened [12]. Together, they can be used to identify effective components for each phase of chronic care smoking treatment.

As per the PBM, we first identified chief challenges of the Motivation phase, ones that reduce either the likelihood of initiating quitting or success in quitting once a quit attempt is made. These challenges include: 1) heavy smoking (although data are mixed [18–23], 2) motivation to smoke that outweighs motivation to quit [18, 19, 24, 25], 3) environmental obstacles to cessation (e.g., smokers in the home: [18, 26]); and, 4) low quitting self-efficacy [18, 24, 27, 28]. On this basis, we identified four Motivation-phase intervention components: Nicotine Patch, Nicotine Gum, Motivational Interviewing, and Behavioral Reduction Counseling. All of the components were designed for translation into real-world healthcare settings, consistent with a pragmatic research approach [29–31].

Nicotine Patch and Gum might help smokers: 1) reduce their smoking [32–34], which, over time, would reduce withdrawal and dependence [35, 36]; 2) reduce smoking-environment and smoking-reward contingencies (e.g., [37]); and 3) enhance quitting self-efficacy by providing prequit practice, blunting withdrawal, and providing a coping response [38], all of which will encourage more successful quit attempts (e.g., [33, 39]; although see [40]). Two types of Nicotine Replacement Therapy (NRT) were selected so that we could examine whether they yield different effects, and also whether they interact.

Motivational Interviewing (MI) was selected to increase intrinsic and personally relevant motives for quitting [3, 41]. There is substantial evidence that MI can increase quit rates when provided during cessation [42–44]; it is much less clear that MI increases quit rates amongst smokers in the Motivation phase who are initially *unwilling to quit* [42, 43, 45–47]

Behavioral Reduction (BR) Counseling was intended to enhance quitting success by reducing cigarette consumption, reducing exposure to cigarette cues (e.g., by increasing smoke-free environments), and encouraging coping practice. These effects might enhance coping skills and quitting self-efficacy, and perhaps decrease the severity of withdrawal during quit attempts. Both smoking reduction and a lower density of environmental smoking cues predict later quitting success [48–50]. However, little evidence exists on the effectiveness of BR Counseling alone during the Motivation phase. Similar counseling has typically been paired with pharmacotherapy in research designs that do not permit disentangling the effects of the two strategies [33, 34, 51] (relevant nonexperimental data exist: [52]).

In sum, this study used efficient research methods [8] to screen four intervention components (Nicotine Patch, Nicotine Gum, MI, and BR Counseling) designed to engage smokers in treatment, reduce smoking heaviness (primary outcome), enhance quitting success, and be easily translated into healthcare settings [53]. The main and interactive

effects of these components were evaluated in this screening experiment to identify promising Motivation-phase components for smokers initially unwilling to quit. Thus, this research yields valuable comparative effectiveness data on multiple intervention components that will help guide future treatment development (via additional factorial experiments or a randomized clinical trial (RCT) that evaluates a package of intervention components as a multicomponent treatment [12, 13]).

METHODS

Procedure

From June, 2010 through October, 2013, participants were recruited from 11 primary care clinics in two healthcare systems in southern Wisconsin using indigenous medical assistants who were prompted by electronic health record (EHR) technology. During clinic visits, identified smokers were invited to participate in a research program to help them reduce their smoking [54]. Interested patients were electronically referred to the research office. Research staff contacted interested patients and assessed eligibility. The inclusion criteria were: 18 years old; 5 cigarettes/day for the previous 6 months; no interest in quitting in the next 30 days but willing to cut down; able to read, write, and speak English; agreeing to complete assessments; planning to remain in the area for at least 6 months; not currently taking bupropion or varenicline; agreeing to use only study smoking medication during the study if reported current NRT use; no medical contraindications to NRT use; and, for women of childbearing potential, agreement to use an approved birth control method.

Eligible patients were invited to return to their primary care clinic to learn more about the study and provide written informed consent.¹ A customized research database program then created a schedule of intervention and assessment contacts, which guided treatment delivery by case managers. The case managers in this study were bachelor's level research staff supervised by licensed clinical psychologists.

There was an initial 6-week Motivation-phase treatment period, and participants could choose to extend the same treatment for another 6 weeks. Participants who chose to extend the treatment continued to receive the same components to which they were initially randomly assigned. In addition, participants could elect to receive Cessation-phase treatment at any point throughout the 6-month study period. Cessation-phase treatment was identical for all participants and consisted of 8 weeks of nicotine patch + gum, and two brief phone counseling sessions. Finally, at 12 and 26 weeks following study enrollment, all participants received a 15 minute follow-up assessment call.

Participants were randomized to treatment conditions using stratified permuted, computer-generated block randomization; we stratified by gender and clinic with a fixed block size of 16 based on the 16 unique possible combinations of intervention components (in random order within each block). Staff were blinded to randomization until eligibility was confirmed but not beyond that point; participants were blinded until consent was provided.

---

¹Although there are 3 related studies (this study, [16, 17].) each is based on an independent sample. There was no crossover in study participation amongst the three studies.

Experimental Design

This 2×2×2 factorial experiment had four factors each comprising an active (ON) condition and control (OFF) condition: 1) Nicotine Patch; 2) Nicotine Gum; 3) MI; and 4) BR Counseling, yielding 16 unique experimental conditions. Participants were randomized to one of the 16 experimental conditions (see Supplemental Table 1) within each participating clinic. Intervention components were designed to be compatible with one another, and to be delivered with fidelity across all treatment combinations using database prompts.

Experimental Factors

The intervention components were designed to address phase-specific challenges and opportunities, and to be readily translatable to real-world practice. See Supplemental Tables 2 and 3 for outlines of counseling protocols and review of fidelity assessments.

Nicotine Patch vs. No Patch—Participants in the ON (active) condition were instructed to use 14-mg patches daily for the 6-week intervention period.

Nicotine Gum vs. No Gum—Participants in the ON condition were instructed to use 2-mg gum for the 6-week intervention period (9/day, 1 piece/1–2 hours) in place of smoking.

Motivational Interviewing (MI) vs. No MI—Participants in the ON condition received an initial 20-minute in-person counseling session followed by three biweekly, 10-minute counseling calls over the 6-week intervention period. Based on Miller and Rollnick [55, 56], the counseling sessions included motivation-building exercises to reinforce intrinsic motivation and to help participants overcome ambivalence about quitting.

Behavioral Reduction (BR) vs. No BR—Participants in the ON condition received an initial 20-minute in-person counseling session followed by 6 weekly 10-minute counseling calls. During these sessions, participants set smoking reduction goals and developed reduction strategies (e.g., delaying smoking, eliminating smoking in specific situations). Participants were also instructed to record daily smoking, which case managers used to identify successes and challenges.

Assessments

Participants completed baseline assessments of vital signs, demographics, and smoking history and dependence (e.g., the Fagerström Test for Nicotine Dependence [FTND]: [57]). During study visits, adverse events, medication adherence, and smoking in the past week were assessed.

Outcome Measures

The primary outcome was percent change in cigarettes smoked per day (CPD) at 26 weeks relative to baseline CPD. CPD change was chosen as the primary outcome because it reflects both smoking reduction and abstinence, and thus captures the net impact of treatment, and because smoking reduction is a valid predictor of future cessation [50, 58]. Percent change also permitted comparison with prior research and controlled for baseline differences in

CPD [33]). The secondary outcomes were percent change in CPD at 12 weeks and 7-day point-prevalence abstinence at 12 and 26 weeks². Assessors were not involved in treatment but were not blind to treatment assignment.

Analytic Plan

Analyses were conducted using SPSS [59]. Initial analyses examined treatment adherence, safety, and patterns and associations with missing data. We computed separate models using effect coding (each coded -1 =OFF condition; $+1$ =ON condition) testing main and interactive effects. We computed separate regression models for the CPD percent change outcome at weeks 12 and 26; models were computed with and without adjusting for a predetermined set of covariates (see below). Participants who did not provide outcome information for the percent change primary outcome were assumed to be smoking at their baseline CPD rate. Sensitivity analyses with multiple imputation (MI) for missing outcome data [60] yielded similar results. Therefore, we present results from analyses where missing=baseline CPD (see Supplemental Table 4 for sensitivity analyses).

Logistic regression was used to analyze 7-day point-prevalence abstinence at 12 and 26 weeks (0 =smoking 1 =abstinent). Participants who did not provide outcome information were assumed to be smoking (i.e., missing=smoking). All CPD change and abstinence analyses were conducted with and without adjusting for covariates: gender, race (White vs. non-White), age, education (up to high school vs. at least some college), the Heaviness of Smoking Index [61], baseline exhaled carbon monoxide, and healthcare system. We discuss results from the unadjusted models only; patterns of statistical significance were consistent across both unadjusted and adjusted models.

RESULTS

Participants

Of the 1046 smokers who expressed initial interest, 517 provided consent (see Figure 1 for CONSORT diagram and Supplemental Materials for sample size justification). Each clinic recruited 23–89 participants. Table 1 provides descriptions of demographic and tobacco dependence characteristics.

Treatment Participation

On average, participants in the MI condition attended a mean of 3.16 ($SD=1.06$) of 4 counseling sessions. Participants in the BR condition attended a mean of 5.31 ($SD=1.86$) of 7 sessions. Participants in the Patch condition used an average of 4.94 patches/week ($SD=2.09$), and those in the Gum condition used an average of 3.61 pieces of gum/day ($SD=2.10$). In addition, 75 (15%) chose to receive a second 6 weeks of the same Motivation-phase treatment to which they had been randomized, and 100 (19%) chose to receive Cessation-phase treatment.

---

²Based upon reviewer recommendations, the designation of outcomes was altered from what was listed in trial registration materials.

Safety

There were no serious adverse events related to study participation. The most common adverse events/condition were nausea (11%: Gum), vivid dreams (20%: Patch), and skin rash (26%: Gum + Patch).

Missing Data

The percentage of participants with missing CPD data decreased from 26% at Week 6 to 13% at Week 26. At Week 26, 44 participants (9%) were missing point-prevalence abstinence data. There were no significant differences in missing data across the contrasting levels of each intervention factor.

Change in Cigarettes Smoked Per Day Outcome

Table 2 presents the CPD percent change for each factor level at 12 and 26 weeks post study enrollment. No treatment main effects were found but a statistically significant 4-way interaction (Patch X Gum X BR X MI) was found at both Weeks 12 and 26, $p's = .01$ (see Table 3).³ When effect coding is used, a four-way interaction means that a three-way interaction involving three experimental factors varies depending on the level of a fourth factor.

As shown in Figure 2a and b, results of the 4-way interaction for the percent CPD change model showed a pattern where some combinations of two components produced substantial reductions in smoking, but only when used with no other components. Across both time points: 1) the combination of Gum and BR, without other components, produced consistent mean CPD reduction (48% smoking reduction at Week 12; 50% reduction at Week 26); and 2) the combination of BR with MI, without other components, also produced substantial mean CPD reductions at both time points (48% at Week 12; 49% at Week 26). While there was a tendency for BR and MI to perform well together, MI did not yield promising effects when used with additional components (e.g., MI + Gum + BR or Patch + MI + Gum: see Figure 2a & b). Figure 2 also suggests that, in general, combinations of 3 or 4 active components suppressed smoking less effectively than did pairs of components.

Finally, the percentage of participants reporting at least a 50% reduction in CPD (cf. [33]) at 12 and 26 Weeks, depending on condition, ranged from about 27–59% across component combinations, with BR + Gum and BR + MI (without other components) producing the greatest proportion who reduced by at least 50% (52% at Week 12 and 59% at Week 26; 50% at Week 12 and 47% at Week 26, respectively).

Cessation Outcome

Table 2 presents self-reported 7-day point-prevalence abstinence rates for each factor level at 12 and 26 weeks post study enrollment. There were significant main effects of Patch and BR at Week 12 (see Table 4); Patch was associated with decreased abstinence at 12 weeks

³Significant 4-way interactions at Weeks 12 and 26 were found amongst a subset of participants who had not quit smoking ($ps = .02$ and $.01$, respectively). Thus, the same reduction effects were found when cessation contributed to the effect, and when it did not. Moreover, the same pattern of significant findings emerged when length of Motivation-phase treatment (6 vs. 12 weeks) was entered as a covariate into the model.

while BR was associated with increased abstinence rates. Moreover, there were two significant 2-way interactions at 26 weeks: Gum $\times$ BR and Gum $\times$ MI (see Table 4 and Figure 3). Participants receiving Gum or BR alone attained the lowest abstinence rates, whereas those receiving neither attained the highest abstinence rates. Those getting both Gum + MI did particularly poorly relative to all other conditions.

We also analyzed 7-day point-prevalence abstinence amongst only those participants who elected to receive Cessation-phase treatment ($n=100$) (see Table 5). There was an antagonistic Gum $\times$ MI interaction at 26 weeks. As Figure 4 shows, Gum with no MI increased abstinence, but this effect was reversed by adding MI. There was also a 26-week synergistic Gum $\times$ BR interaction at $p = .06$, suggesting that Gum improved abstinence when paired with BR, and reduced abstinence when not paired with BR (see Figure 4).

DISCUSSION

The goal of this screening experiment was to identify Motivation-phase intervention components that yield patterns of promising effects on smoking reduction and abstinence when used in a primary care setting. None of the four intervention components (Nicotine Patch, Nicotine Gum, MI Counseling, BR Counseling) yielded significant main effects on percent CPD change. However, a significant Patch $\times$ Gum $\times$ MI $\times$ BR interaction at both 12 and 26 weeks showed that component effectiveness was influenced by the co-occurrence of components (Figure 2). In particular Gum + BR and BR + MI were relatively effective at reducing CPD at both 12 and 26 weeks. These results were obtained both when abstainers were, and were not, included in analyses. The results also showed that no combinations of three or more components were especially effective (Figure 2a and b), suggesting a cost of treatment complexity [62, 63]. Further, the percentage of participants showing meaningful reductions compared favorably with much longer trials of Motivation-phase treatments. The Moore et al. meta-analysis [33] showed smoking reductions of 50% at treatment end in about 22% of the participants receiving active treatment. Our results show that 27–59% of participants reported meaningful reductions ($>50\%$), depending on condition, with some of this reduction reflecting cessation.

Motivation-phase intervention components appeared to influence cessation success. In the full sample, participants who received BR were more likely to be abstinent than those who did not receive BR whereas the Patch produced lower abstinence rates relative to no Patch. Gum, depending on the components with which it was paired, produced especially low 26-week abstinence rates (Figure 3). However, amongst participants who entered Cessation-phase treatment, receiving Gum during the Motivation-phase was related to the highest abstinence rates; pairing MI with Gum reduced this benefit (Gum + no MI = 58% abstinent vs. Gum + MI = 24%; see Figure 4). Thus, the effectiveness of Motivation-phase Gum depended upon the components with which it was paired and the treatment phase in which it was used (i.e. Motivation or Cessation).

Even though the participants in this study were initially unwilling to quit, the point-prevalence abstinence rates amongst those who opted to receive formal cessation treatment were relatively high for a modestly intense cessation intervention (38% abstinent across all

conditions: cf. [3]). The 26-week abstinence rate for the full sample, across all intervention conditions, was 11%, comparable to abstinence rates obtained with *active* Motivation-phase intervention in other studies (7–20%: [33, 64, 65]). However, those studies typically lasted for 6–24 months, versus 6–12 weeks in the current experiment. The current results may compare favorably to earlier, longer studies because those studies did not provide a cessation intervention for smokers who had become ready to quit [3, 66].

Although combination NRT and MI are proven interventions for both cessation and inducing quit attempts [3, 33, 43, 67], in this Motivation-phase experiment neither yielded meaningful benefit. For instance, MI reduced the beneficial effect of Gum on abstinence rates (e.g., Figure 4). Similarly, the Patch and Gum did not yield meaningful additive or synergistic effects in abstinence analyses with the full sample. These differences in intervention component effects across the Motivation and Cessation phases, if replicated, underscore the importance of experimentally evaluating components for each treatment phase [13]. This research also highlights the value of examining both main and interactive effects when developing integrated treatments [8]. The results suggest that component interaction effects of meaningful magnitude may occur; such effects would not have been detected in a typical RCT [68].

This research supports the feasibility of chronic care treatment for smoking [69, 70]. A meaningful percentage of smokers in primary care who were initially unwilling to quit entered (30%: [7]) and adhered to Motivation-phase treatment with a reduction goal. Also, after brief Motivation-phase treatment, 19% of participants opted for formal Cessation-phase treatment, and prior exposure to particular Motivation-phase intervention components was especially related to abstinence (e.g., Gum when not accompanied by MI, and perhaps Gum + BR). The latter finding does not permit strong inference, however, because the Motivation-phase components might have affected either cessation ability itself, or participant self-selection into the cessation treatment.

One might question either the strength of the effects obtained, or the strength of the evidence. For instance, in the overall sample, there were no significant main effects for intervention components with regard to percent CPD change, although BR did produce a main effect by enhancing abstinence rates. Moreover, it is difficult to draw strong inferences about particular components from higher order interactions, particularly those that were not hypothesized a priori. However, unlike interactions involving person factors that vary randomly, these interactions involve factors that have been experimentally manipulated in a controlled fashion, increasing the likelihood of replicability. Future research is required to determine whether the interactions we found will replicate. In addition, main effects might have been obtained with longer treatment duration or higher dosages of the NRT agents, features that are typical in prior research in this area (e.g., [33]). Also, this study specifically recruited smokers who were willing to cut down but not quit; the findings might not generalize well to other smokers (e.g., those not interested in cutting down). Finally, self-reports of abstinence were not biochemically confirmed. Future Motivation-phase research should extend the length of Motivation-phase treatment, explore other promising components (e.g., the 5 Rs: [3, 51]), and use a broader range of smokers who are unwilling to quit.

Conclusion

Using the Phase-Based Model of Smoking Intervention [13] and the Multiphase Optimization Strategy [8], this research found that two Motivation-phase intervention components may be relatively effective with smokers who are willing to reduce their smoking but not quit: Nicotine Gum and Behavioral Reduction Counseling. These components were present in combinations that produced the most consistent and marked reductions in smoking across time, and BR improved abstinence in the full sample. There was also evidence that Gum, and possibly BR combined with Gum, could enhance long-term abstinence amongst those making aided quit attempts. Results also revealed that the effectiveness of intervention components was often meaningfully affected by the components with which they were paired. The promising intervention components identified in this research should undergo further evaluation, including additional factorial experiments or an RCT that evaluates a package of intervention components.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

This research was supported by grants 9P50CA143188 and 1K05CA139871 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention and by the Wisconsin Partnership Program. This work was carried out in part while Dr. Schlam was a Primary Care Research Fellow supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. Dr. Loh is also supported by NSF grant DMS-1305725. Dr. Collins is also supported by NIH grants P50DA10075 and R01DK097364. Dr. Cook is supported by Merit Review Award 101CX00056 from the US Department of Veterans Affairs.

Dr. Loh is partially supported by a grant from Eli Lilly and Company for research that is unrelated to smoking or tobacco dependence treatment.

We would like to acknowledge the staff at Aurora Health Care, *Deancare*, and Epic Systems Corporation for their collaboration in this research. We are very grateful to the staff and students at the Center for Tobacco Research and Intervention in the University of Wisconsin School of Medicine and Public Health for their help with this research.

REFERENCES

1. Agaku IT, King BA, Dube SR, Centers for Disease Control and Prevention. Current cigarette smoking among adults - United States, 2005–2012. *MMWR*. 2014; 63:29–34. [PubMed: 24430098]
2. Centers for Disease Control and Prevention. Current cigarette smoking among adults - United States, 2011. *MMWR*. 2012; 61:889–894. [PubMed: 23134971]
3. Fiore, MC.; Jaen, CR.; Baker, TB.; Bailey, WC.; Benowitz, N.; Curry, SJ., et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services, U.S. Public Health Service; 2008.
4. Bentz CJ, Bayley KB, Bonin KE, Fleming L, Hollis JF, McAfee T. The feasibility of connecting physician offices to a state-level tobacco quit line. *Am J Prev Med*. 2006; 30:31–37. [PubMed: 16414421]
5. Etter JF, Perneger TV, Ronchi A. Distributions of smokers by stage: international comparison and association with smoking prevalence. *Prev Med*. 1997; 26:580–585. [PubMed: 9245682]
6. Wewers ME, Stillman FA, Hartman AM, Shopland DR. Distribution of daily smokers by stage of change: Current Population Survey results. *Prev Med*. 2003; 36:710–720. [PubMed: 12744915]
7. Piper ME, Baker TB, Mermelstein R, Collins LM, Fraser DL, Jorenby DE, et al. Recruiting and engaging smokers in treatment in a primary care setting: developing a chronic care model

implemented through a modified electronic health record. *Transl Behav Med.* 2013; 3:253–263. [PubMed: 24073176]

8. Collins LM, Baker TB, Mermelstein RJ, Piper ME, Jorenby DE, Smith SS, et al. The Multiphase Optimization Strategy for engineering effective tobacco use interventions. *Ann Behav Med.* 2011; 41:208–226. [PubMed: 21132416]
9. Collins LM, Murphy SA, Nair VN, Strecher VJ. A strategy for optimizing and evaluating behavioral interventions. *Ann Behav Med.* 2005; 30:65–73. [PubMed: 16097907]
10. Collins LM, Murphy SA, Strecher V. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): new methods for more potent eHealth interventions. *Am J Prev Med.* 2007; 32(5 Suppl):S112–S118. [PubMed: 17466815]
11. Collins LM, Dziak JJ, Kugler KC, Trail JB. Factorial experiments: efficient tools for evaluation of intervention components. *Am J Prev Med.* 2014; 47:498–504. [PubMed: 25092122]
12. Baker TB, Collins LM, Mermelstein R, Piper ME, Schlam TR, Cook JW, et al. Enhancing the effectiveness of smoking treatment research: conceptual bases and progress. *Addiction.* under review.
13. Baker TB, Mermelstein R, Collins LM, Piper ME, Jorenby DE, Smith SS, et al. New methods for tobacco dependence treatment research. *Ann Behav Med.* 2011; 41:192–207. [PubMed: 21128037]
14. Schlam TR, Baker TB. Interventions for tobacco smoking. *Annu Rev Clin Psychol.* 2013; 9:675–702. [PubMed: 23297788]
15. Cook JW, Baker TB, Fiore MC, Smith SS, Fraser D, Bolt DM, et al. Comparative effectiveness of motivation phase intervention components for use with smokers unwilling to quit: a factorial screening experiment. *Addiction.* under review.
16. Piper ME, Fiore MC, Smith SS, Fraser D, Bolt DM, Collins LM, et al. Identifying effective intervention components for smoking cessation: a factorial screening experiment. *Addiction.* under review.
17. Schlam TR, Fiore MC, Smith SS, Fraser D, Bolt DM, Collins LM, et al. Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment. *Addiction.* under review.
18. Li L, Feng G, Jiang Y, Yong HH, Borland R, Fong GT. Prospective predictors of quitting behaviours among adult smokers in six cities in China: findings from the International Tobacco Control (ITC) China Survey. *Addiction.* 2011; 106:1335–1345. [PubMed: 21438942]
19. Vangeli E, Stapleton J, Smit ES, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. *Addiction.* 2011; 106:2110–2121. [PubMed: 21752135]
20. Zhou X, Nonnemaker J, Sherrill B, Gilseman AW, Coste F, West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. *Addict Behav.* 2009; 34:365–373. [PubMed: 19097706]
21. Cropsey KL, Kristeller JL. Motivational factors related to quitting smoking among prisoners during a smoking ban. *Addict Behav.* 2003; 28:1081–1093. [PubMed: 12834652]
22. Fagan P, Augustson E, Backinger CL, O'Connell ME, Vollinger RE Jr, Kaufman A, et al. Quit attempts and intention to quit cigarette smoking among young adults in the United States. *Am J Public Health.* 2007; 97:1412–1420. [PubMed: 17600244]
23. Fidler JA, West R. Enjoyment of smoking and urges to smoke as predictors of attempts and success of attempts to stop smoking: a longitudinal study. *Drug Alcohol Depend.* 2011; 115:30–34. [PubMed: 21111539]
24. Yong HH, Borland R. Functional beliefs about smoking and quitting activity among adult smokers in four countries: findings from the International Tobacco Control Four-Country Survey. *Health Psychol.* 2008; 27(3 Suppl):S216–S223. [PubMed: 18979974]
25. West R, McEwen A, Bolling K, Owen L. Smoking cessation and smoking patterns in the general population: a 1-year follow-up. *Addiction.* 2001; 96:891–902. [PubMed: 11399220]
26. Tucker JS, Ellickson PL, Orlando M, Klein DJ. Predictors of attempted quitting and cessation among young adult smokers. *Prev Med.* 2005; 41:554–561. [PubMed: 15917052]

27. Gwaltney CJ, Shiffman S, Paty JA, Liu KS, Kassel JD, Gnys M, et al. Using self-efficacy judgments to predict characteristics of lapses to smoking. *J Consult Clin Psychol.* 2002; 70:1140–1149. [PubMed: 12362964]
28. Keller S, Nigg CR, Jäkke C, Baum E, Basler H-D. Self-efficacy, decisional balance and the stages of change for smoking cessation in a German sample. *Swiss J Psychol.* 1999; 58:101–110.
29. Glasgow RE, Orleans CT, Wagner EH. Does the chronic care model serve also as a template for improving prevention? *Milbank Q.* 2001; 79:579–612. iv–v. [PubMed: 11789118]
30. McLellan A, Lewis DC, O’Brein CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. *JAMA.* 2000; 284:1689–1695. [PubMed: 11015800]
31. Riley WT, Glasgow RE, Etheredge L, Abernethy AP. Rapid, responsive, relevant (R3) research: a call for a rapid learning health research enterprise. *Clin Transl Med.* 2013; 2:10. [PubMed: 23663660]
32. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. *J Clin Psychopharmacol.* 2002; 22:487–495. [PubMed: 12352272]
33. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. *BMJ.* 2009; 338:b1024. [PubMed: 19342408]
34. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. *Am J Prev Med.* 2009; 36:96–104. e1. [PubMed: 19135903]
35. Baker TB, Breslau N, Covey L, Shiffman S. DSM criteria for tobacco use disorder and tobacco withdrawal: a critique and proposed revisions for DSM-5. *Addiction.* 2012; 107:263–275. [PubMed: 21919989]
36. Baker TB, Piper ME, Schlam TR, Cook JW, Smith SS, Loh WY, et al. Are tobacco dependence and withdrawal related amongst heavy smokers? Relevance to conceptualizations of dependence. *J Abnorm Psychol.* 2012; 121:909–921. [PubMed: 22642839]
37. Schuz N, Ferguson SG. An exploratory examination of the mechanisms through which pre-quit patch use aids smoking cessation. *Psychopharmacology (Berl).* 2014; 231:2603–2609. [PubMed: 24408215]
38. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB. Psychological mediators of bupropion sustained-release treatment for smoking cessation. *Addiction.* 2008; 103:1521–1533. [PubMed: 18783504]
39. Beard E, Aveyard P, Brown J, West R. Assessing the association between the use of NRT for smoking reduction and attempts to quit smoking using propensity score matching. *Drug Alcohol Depend.* 2012; 126:354–361. [PubMed: 22748518]
40. Levy DE, Thorndike AN, Biener L, Rigotti NA. Use of nicotine replacement therapy to reduce or delay smoking but not to quit: prevalence and association with subsequent cessation efforts. *Tob Control.* 2007; 16:384–389. [PubMed: 18048614]
41. Curry SJ, Grothaus L, McBride C. Reasons for quitting: Intrinsic and extrinsic motivation for smoking cessation in a population-based sample of smokers. *Addict Behav.* 1997; 22:727–739. [PubMed: 9426790]
42. Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. *Tob Control.* 2010; 19:410–416. [PubMed: 20675688]
43. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. *Cochrane Database Syst Rev.* 2010; (1):CD006936. [PubMed: 20091612]
44. Lindqvist H, Forsberg LG, Forsberg L, Rosendahl I, Enebrink P, Helgason AR. Motivational interviewing in an ordinary clinical setting: a controlled clinical trial at the Swedish National Tobacco Quitline. *Addict Behav.* 2013; 38:2321–2324. [PubMed: 23584193]
45. Audrain-McGovern J, Stevens S, Murray PJ, Kinsman S, Zuckoff A, Pletcher J, et al. The efficacy of motivational interviewing versus brief advice for adolescent smoking behavior change. *Pediatrics.* 2011; 128:e101–e111. [PubMed: 21690120]

46. Davis MF, Shapiro D, Windsor R, Whalen P, Rhode R, Miller HS, et al. Motivational interviewing versus prescriptive advice for smokers who are not ready to quit. *Patient Educ Couns*. 2011; 83:129–133. [PubMed: 20627440]
47. Rohsenow DJ, Martin RA, Monti PM, Colby SM, Day AM, Abrams DB, et al. Motivational interviewing versus brief advice for cigarette smokers in residential alcohol treatment. *J Subst Abuse Treat*. 2014; 46:346–355. [PubMed: 24210533]
48. Bolt DM, Piper ME, McCarthy DE, Japuntich SJ, Fiore MC, Smith SS, et al. The Wisconsin Predicting Patients' Relapse questionnaire. *Nicotine Tob Res*. 2009; 11:481–492. [PubMed: 19372573]
49. Broms U, Korhonen T, Kaprio J. Smoking reduction predicts cessation: longitudinal evidence from the Finnish adult twin cohort. *Nicotine Tob Res*. 2008; 10:423–427. [PubMed: 18324560]
50. Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. *Nicotine Tob Res*. 2006; 8:739–749. [PubMed: 17132521]
51. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. *J Consult Clin Psychol*. 2004; 72:371–381. [PubMed: 15279521]
52. Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. *Addiction*. 2005; 100:1074–1089. [PubMed: 16042638]
53. Glasgow RE. What does it mean to be pragmatic? Pragmatic methods, measures, and models to facilitate research translation. *Health Educ Behav*. 2013; 40:257–265. [PubMed: 23709579]
54. Fraser D, Christiansen BA, Adsit R, Baker TB, Fiore MC. Electronic health records as a tool for recruitment of participants' clinical effectiveness research: lessons learned from tobacco cessation. *Transl Behav Med*. 2013; 3:244–252. [PubMed: 24073175]
55. Miller, WR.; Rollnick, S. *Motivational interviewing: Preparing people for change*. 2nd ed. New York: Guilford Press; 2002.
56. Rollnick, S.; Mason, P.; Butler, C. *Health behavior change: A guide for practitioners*. Edinburgh: Churchill Livingstone; 1999.
57. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict*. 1991; 86:1119–1127. [PubMed: 1932883]
58. Klemperer EM, Hughes JR. Does the magnitude of reduction in cigarettes per day predict smoking cessation? a qualitative review. *Nicotine Tob Res*. 2015 [Epub ahead of print].
59. IBM Corporation. *IBM SPSS Statistics for Windows, Version 22.0*. Armonk, NY: IBM Corporation; 2013.
60. Hedeker D, Mermelstein RJ, Demirtas H. Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. *Addiction*. 2007; 102:1564–1573. [PubMed: 17854333]
61. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. *Br J Addict*. 1989; 84:791–799. [PubMed: 2758152]
62. Baker TB, Hawkins R, Pingree S, Roberts LJ, McDowell HE, Shaw BR, et al. Optimizing eHealth breast cancer interventions: which types of eHealth services are effective? *Transl Behav Med*. 2011; 1:134–145. [PubMed: 21709810]
63. Fraser D, Kobinsky K, Smith SS, Kramer J, Theobald WE, Baker TB. Five population-based interventions for smoking cessation: a MOST trial. *Transl Behav Med*. 2014; 4:382–390. [PubMed: 25584087]
64. Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? *Addict Behav*. 2011; 36:764–768. [PubMed: 21420791]
65. Glasgow RE, Gaglio B, Estabrooks PA, Marcus AC, Ritzwoller DP, Smith TL, et al. Long-term results of a smoking reduction program. *Med Care*. 2009; 47:115–120. [PubMed: 19106739]
66. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. *Cochrane Database Syst Rev*. 2012; 12:CD009670. [PubMed: 23235680]
67. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev*. 2012; 10:CD008286. [PubMed: 23076944]

68. Collins LM, Chakraborty B, Murphy SA, Strecher V. Comparison of a phased experimental approach and a single randomized clinical trial for developing multicomponent behavioral interventions. *Clin Trials*. 2009; 6:5–15. [PubMed: 19254929]
69. Ellerbeck EF, Mahnken JD, Cupertino AP, Cox LS, Greiner KA, Mussulman LM, et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. *Ann Intern Med*. 2009; 150:437–446. [PubMed: 19349629]
70. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. *Arch Intern Med*. 2011; 171:1894–1900. [PubMed: 22123795]

Figure 1.
CONSORT diagram

Mean Percent Reduction in Cigarettes Per Day (CPD) at Week 12

a.

b.

Figure 2.

a. Bar graph showing interactions for mean percent reduction in cigarettes per day at 12 weeks post study enrollment.

b. Bar graph showing interactions for mean percent reduction in cigarettes per day at 26 weeks post study enrollment.

Figure 3.

Bar graphs for Gum X BR and Gum X MI interactions for the 26-week point-prevalence abstinence model for the full sample ($n = 517$)

Figure 4.

Bar graphs showing Gum X MI and Gum X BR interactions for the 26-week point-prevalence abstinence model among participants who received cessation treatment ($n=100$)

Table 1

Demographic and Smoking History Characteristics

	Total Sample	Nicotine Patch		Nicotine Gum		Motivational Interviewing		Behavioral Reduction Counseling	
		On	Off	On	Off	On	Off	On	Off
Women (%)	63.4	63.4	63.5	63.6	63.2	63.2	63.6	62.7	64.2
Health System A (%)	55.1	55.1	55.2	53.8	56.5	57.7	52.7	57.7	52.5
High School diploma or GED only (%)	38.4	45.7	30.7	38.4	38.5	40.2	36.7	40.2	36.7
At least some college (%)	61.6	54.0	69.0	61.6	61.5	59.8	63.3	63.3	63.3
White (%)	91.1	91.7	90.5	90.5	91.7	90.5	91.7	92.3	89.9
African-American (%)	4.8	4.2	5.6	5.3	4.3	4.7	4.9	4.6	5.1
Hispanic (%)	1.0	1.9	.8	1.6	1.2	2.1	0.8	0.8	2.0
Age (mean, SD)	47.0 (14.4)	47.1 (14.15)	47.0 (4.6)	46.6 (14.6)	47.5 (14.4)	46.3 (4.8)	47.7 (14.2)	46.3 (14.5)	47.7 (14.2)
Cigs/day (mean, SD)	17.5 (7.8)	18.3 (8.4)	16.4 (7.5)	17.9 (7.8)	16.9 (8.2)	17.3 (8.3)	17.4 (7.7)	17.0 (8.1)	17.8 (8.0)
FTND (mean, SD)	4.8 (2.1)	4.9 (2.1)	4.6 (2.0)	4.7 (2.2)	4.9 (2.0)	4.8 (2.1)	4.8 (2.01)	4.8 (2.1)	4.8 (2.0)
Heaviness of Smoking Index (mean, SD)	3.1 (1.4)	3.0 (1.4)	3.1 (1.4)	3.0 (1.4)	3.1 (1.4)	3.0 (1.6)	3.1 (1.2)	3.1 (1.5)	3.0 (1.2)
Baseline CO (mean, SD)	21.3 (11.8)	21.6 (10.2)	21.1 (12.9)	19.0 (10.8)	23.2 (12.3)	20.2 (13.0)	22.2 (10.7)	18.4 (10.6)	23.9 (12.3)

Self-Reported Mean CPD Percent Reduction and Point-Prevalence Abstinence Rates at 12 and 26 Weeks Post-Study Enrollment

Table 2

Factor	Mean Percent CPD Reduction at 12 Weeks (SD)		Mean Percent CPD Reduction at 26 Weeks (SD)		Percent Abstinent at 12 Weeks		Percent Abstinent at 26 Weeks	
	On	Off	On	Off	On	Off	On	Off
Nicotine Patch	37.0(34.6)	37.6(36.4)	38.7(36.2)	38.9(37.1)	5.7	11.1	9.4	12.3
Nicotine Gum	37.7(35.0)	36.9(35.9)	37.4(36.2)	40.2(36.9)	8.7	7.9	9.1	12.6
Motivational Interviewing	35.3(35.9)	39.2(34.9)	37.2(35.6)	40.2(37.5)	8.3	8.3	9.1	12.5
Behavioral Reduction Counseling	38.4(36.2)	36.2(34.6)	38.6(36.3)	38.9(36.9)	10.8	5.8	10.8	10.9

Note. On = Factor was present; Off = Factor was not present

Table 3

Unadjusted and Adjusted Regression Analyses for Percent Change in Cigarettes Smoked per Day in the Past Week at Weeks 12 and 26 Post-Study Enrollment

	12 Week						26 Week					
	Unadjusted			Adjusted*			Unadjusted			Adjusted*		
	β	t	p	β	t	p	β	t	p	β	t	p
Model Effect												
Nicotine Patch	-.01	-1.19	.85	-.01	-1.14	.89	-.00	-.03	.98	-.00	-.05	.96
Nicotine Gum	.01	.25	.80	.01	.17	.87	-.04	-.84	.40	-.05	-1.07	.29
BR	.03	.74	.50	.02	.54	.59	-.00	-.01	.99	-.01	-.17	.87
MI	-.05	-1.23	.22	-.06	-1.35	.18	-.04	-.97	.33	-.05	-1.06	.29
Patch X Gum	-.04	-.79	.43	-.03	-.76	.45	-.04	-.82	.41	-.04	-.81	.42
Patch X BR	-.08	-1.80	.07	-.08	-1.73	.09	-.07	-1.51	.13	-.06	-1.40	.16
Patch X MI	-.07	-1.54	.12	-.06	-1.27	.21	-.01	-.15	.88	.00	-.00	.99
Gum X BR	.007	.15	.88	.01	.12	.91	.03	.77	.44	.03	.76	.45
Gum X MI	-.08	-1.92	.06	-.09	-1.96	.05	-.05	-1.10	.27	-.06	-1.34	.18
BR X MI	.02	.36	.72	.01	.20	.84	.01	.15	.89	.00	.04	.97
Patch X Gum X BR	.02	.50	.62	.02	.43	.67	.07	1.51	.13	.06	1.45	.15
Patch X Gum X MI	.00	.03	.98	.01	.15	.88	.02	.43	.67	.03	.59	.56
Patch X BR X MI	.00	.08	.93	.00	.03	.98	.02	.37	.71	.02	.35	.73
Gum X BR X MI	.01	.33	.75	.02	.37	.71	-.04	-.99	.32	-.04	-1.00	.32
Patch X Gum X BR X MI	.11	2.51	.01	.11	2.58	.01	.12	2.65	.01	.12	2.66	.01

Note. Bold indicates $p < .05$.

* Adjusted model controlled for gender, race (White vs. non-White), age, education (up to high school diploma vs. at least some college), healthcare system (A vs. B), Heaviness of Smoking Index, and baseline carbon monoxide.

Table 4 Unadjusted and Adjusted Logistic Regression Analyses for 7-Day Point-Prevalence Abstinence at Weeks 12 and 26 Post-Study Enrollment ($N=517$)

	12 Week				26 Week			
Model Effect ^a	Unadjusted		b Adjusted		Unadjusted		*Adjusted	
	b	p-value	b	p-value	b	p-value	b	p-value
Nicotine Patch	-.45	.03	-.38	.06	-.21	.26	-.17	.38
Nicotine Gum	-.03	.89	-.04	.84	-.28	.15	-.30	.12
Behavioral Reduction	.42	.04	.42	.04	.08	.68	.07	.72
Motivational Interviewing (MI)	-.03	.88	-.04	.83	-.30	.11	-.30	.12
Patch X Gum	-.11	.57	-.14	.49	-.06	.72	-.08	.67
Patch X BR	.16	.42	.20	.34	-.25	.14	-.22	.20
Patch X MI	-.01	.96	-.01	.97	-.10	.54	-.11	.53
Gum X BR	.12	.54	.13	.51	.45	.02	.49	.01
Gum X MI	-.10	.61	-.08	.70	-.40	.04	-.41	.04
BR X MI	.15	.43	.12	.53	.24	.20	.24	.21
Patch X Gum X BR	.30	.13	.27	.19	.18	.30	.19	.29
Patch X Gum X MI	-.05	.78	-.03	.89	.13	.49	.13	.50
Patch X BR X MI	-.10	.60	-.07	.72	-.09	.62	-.07	.71
Gum X BR X MI	-.04	.82	-.06	.74	.05	.78	.03	.87

Note. Bold indicates $p < .05$.^aThe model included effects up to a 3-way interaction because higher order interactions did not converge.^b Adjusted model controlled for gender, race (White vs. non-White), age, education (up to high school diploma vs. at least some college), healthcare system (A vs. B), Heaviness of Smoking Index, and baseline carbon monoxide.

Table 5

Unadjusted and Adjusted Logistic Regression Analyses for 7-Day Point-Prevalence Abstinence at Weeks 12 and 26 Post-Study Enrollment Among Those Who Underwent an Aided Quit Attempt ($n=100$)

	12 Week				26 Week			
	Unadjusted		Adjusted ^b		Unadjusted		*Adjusted	
Model Effect ^a	<i>b</i>	<i>p-value</i>	<i>b</i>	<i>p-value</i>	<i>b</i>	<i>p-value</i>	<i>b</i>	<i>p-value</i>
Nicotine Patch	-.47	.08	-.47	.11	-.26	.30	-.30	.29
Nicotine Gum	.33	.23	.22	.46	.14	.60	.09	.77
Behavioral Reduction	.48	.06	.47	.11	-.14	.62	-.22	.52
Motivational Interviewing (MI)	.15	.57	.29	.35	-.28	.28	-.39	.20
Patch X Gum	.22	.41	.11	.71	.01	.97	-.02	.95
Patch X BR	.40	.13	.46	.10	-.01	.99	.10	.76
Patch X MI	.02	.94	.18	.55	-.38	.16	-.39	.20
Gum X BR	-.11	.66	-.14	.59	.61	.06	.64	.06
Gum X MI	-.28	.24	-.25	.34	-.84	.01	-1.00	.00
BR X MI	.08	.75	-.03	.92	.46	.15	.45	.19

Note. Bold indicates $p < .05$.

^aThe model included effects up to a 2-way interaction because higher order interactions did not converge.

^b Adjusted model controlled for gender, race (White vs. non-White), age, education (up to high school diploma vs. at least some college), healthcare system (A vs. B), Heaviness of Smoking Index, and baseline carbon monoxide.